🇺🇸 Propofol / Remifentanil in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 6
Most-reported reactions
- Drug Ineffective — 2 reports (33.33%)
- Condition Aggravated — 1 report (16.67%)
- Hypokalaemia — 1 report (16.67%)
- Restrictive Pulmonary Disease — 1 report (16.67%)
- Venoocclusive Liver Disease — 1 report (16.67%)
Other Anesthesia approved in United States
Frequently asked questions
Is Propofol / Remifentanil approved in United States?
Propofol / Remifentanil does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Propofol / Remifentanil in United States?
University General Hospital of Patras is the originator. The local marketing authorisation holder may differ — check the official source linked above.